<DOC>
	<DOC>NCT00349427</DOC>
	<brief_summary>This study is designed to demonstrate that addition of rosiglitazone (4mg) to insulin in Type 2 diabetes mellitus subjects who have not achieved glycemic goals on insulin injections alone is efficacious in terms of improving glycemic control.</brief_summary>
	<brief_title>A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion: Patients with type 2 Diabetes mellitus on a minimum dose of 30 units/day insulin monotherapy continuously for at least 8 weeks If Patients are taking another oral antidiabetic agent may stop their oral agent and adjust their insulin dose properly over 8 weeks prior to screening if they are asked by doctor who considers him/her suitable for study in all other respects, and the HbA1c level&gt;7.5%. Exclusion: Fasting plasma glucose &gt;13 mmol/L at screening Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months Drug abuse Women pregnant or lactating Use any rosiglitazone like drug in 3 months Use more than one oral antidiabetic agent in 2 months Uncontrolled hypertension Chronic heart failure Anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Insulin</keyword>
	<keyword>BRL49653 /rosiglitazone</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>